Header Logo

Connection

WILLIAM WONG to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications WILLIAM WONG has written about Cost-Benefit Analysis.
WILLIAM WONG
Connection Strength
3.360
Cost-Benefit Analysis
  1. A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening. Curr Oncol. 2025 Apr 11; 32(4).
    View in: PubMed
    Score: 0.769
  2. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat. 2015 Jun; 151(3):639-52.
    View in: PubMed
    Score: 0.387
  3. A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. Pharmacoeconomics. 2025 Jul; 43(7):765-778.
    View in: PubMed
    Score: 0.192
  4. CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis. Med Decis Making. 2024 04; 44(3):296-306.
    View in: PubMed
    Score: 0.178
  5. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). Pharmacoeconomics. 2023 08; 41(8):945-980.
    View in: PubMed
    Score: 0.169
  6. Cost-utility analysis of a multispecialty interprofessional team dementia care model in Ontario, Canada. BMJ Open. 2023 04 19; 13(4):e064882.
    View in: PubMed
    Score: 0.168
  7. Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. Pharmacoeconomics. 2023 04; 41(4):413-425.
    View in: PubMed
    Score: 0.165
  8. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
    View in: PubMed
    Score: 0.142
  9. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. Hum Reprod. 2020 02 29; 35(2):434-445.
    View in: PubMed
    Score: 0.135
  10. A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value Health. 2020 01; 23(1):127-137.
    View in: PubMed
    Score: 0.133
  11. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020 03; 25(3):e512-e519.
    View in: PubMed
    Score: 0.132
  12. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. J Oncol Pract. 2018 05; 14(5):e280-e294.
    View in: PubMed
    Score: 0.118
  13. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist. 2018 02; 23(2):225-233.
    View in: PubMed
    Score: 0.114
  14. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015 Feb; 150(1):169-80.
    View in: PubMed
    Score: 0.095
  15. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015 Feb 17; 187(3):E110-E121.
    View in: PubMed
    Score: 0.095
  16. Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada. Leuk Lymphoma. 2025 Oct; 66(10):1875-1883.
    View in: PubMed
    Score: 0.049
  17. Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada. Viruses. 2024 07 31; 16(8).
    View in: PubMed
    Score: 0.046
  18. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada. Pharmacoeconomics. 2024 Apr; 42(4):393-407.
    View in: PubMed
    Score: 0.044
  19. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023 Mar; 29(2):488-497.
    View in: PubMed
    Score: 0.041
  20. Cost effectiveness of treatment strategies for high risk prostate cancer. Cancer. 2022 11 01; 128(21):3815-3823.
    View in: PubMed
    Score: 0.040
  21. The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. Liver Int. 2020 06; 40(6):1282-1291.
    View in: PubMed
    Score: 0.034
  22. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int. 2020 01; 40(1):51-59.
    View in: PubMed
    Score: 0.033
  23. Cost Effectiveness of Hepatocellular Carcinoma Surveillance?After a Sustained Virologic Response to Therapy?in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1840-1849.e16.
    View in: PubMed
    Score: 0.031
  24. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. J Oncol Pract. 2016 06; 12(6):e710-23.
    View in: PubMed
    Score: 0.026
  25. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better? Vaccine. 2016 Apr 07; 34(16):1936-44.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.